BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/ CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N-aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.
BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancerpatients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/ CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N-aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.
Authors: Sarah Boudova; Haishan Li; Mohammad M Sajadi; Robert R Redfield; Cristiana Cairo; C David Pauza Journal: J Infect Dis Date: 2013-04-01 Impact factor: 5.226
Authors: James T Frencher; Hongbo Shen; Lin Yan; Jessica O Wilson; Nancy E Freitag; Alicia N Rizzo; Crystal Y Chen; Zheng W Chen Journal: J Leukoc Biol Date: 2014-08-11 Impact factor: 4.962
Authors: Rowan T Chlebowski; Zhao Chen; Jane A Cauley; Garnet Anderson; Rebecca J Rodabough; Anne McTiernan; Dorothy S Lane; Joann E Manson; Linda Snetselaar; Shagufta Yasmeen; Mary Jo O'Sullivan; Monika Safford; Susan L Hendrix; Robert B Wallace Journal: J Clin Oncol Date: 2010-06-21 Impact factor: 44.544